癌症合并COVID-19入住ICU患者的临床特征、管理与结局
该单中心回顾性队列纳入2020年3月1日至6月30日美国一家三级癌症中心两个内科-外科ICU的89例成人癌症合并COVID-19患者(当前或过去<2年癌症诊断)。中位年龄65岁,57%实体瘤、42%血液肿瘤,69%近90天接受抗肿瘤治疗。67%需机械通气,56%需俯卧位,28%行气管切开,71%需血管活性药。医院死亡率45%(40/89),机械通气者53%(32/60);9个月随访死亡率54%(48/89)。血液肿瘤、更高疾病严重度与器官衰竭评分、需要有创机械通气及血管活性药、入ICU时较低血红蛋白和血小板计数、较高D-二聚体与更高医院死亡率显著相关。
要点
- 癌症合并COVID-19入住ICU患者医院死亡率为45%(40/89),需要有创机械通气者死亡率升至53%(32/60)。
- 71%需血管活性药、67%需机械通气、56%需俯卧位、28%行气管切开,提示该人群高呼吸循环支持需求。
- 血液肿瘤、更高疾病严重度与器官衰竭评分、需要有创机械通气及血管活性药与更高医院死亡率显著相关。
- 入ICU时较低血红蛋白、较低血小板计数和较高D-二聚体与更高医院死亡率显著相关。
- ICU和医院住院时间分别为10天和26天;9个月随访死亡率为54%(48/89),出院后 intermediate-term 结局良好。
适用人群与场景
- 纳入:2020年3月1日至6月30日入住美国一家三级癌症中心两个内科-外科ICU的连续成人(≥18岁)患者,当前或过去<2年诊断为癌症,且COVID-19检测阳性。
- 排除:原文未提及。
- 场景:ICU(两个内科-外科ICU),病情阶段为重症需ICU监护。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:单中心回顾性队列研究;样本量89例;中心数1个(两个内科-外科ICU)。
- 人群:成人癌症(当前或过去<2年诊断)合并COVID-19入住ICU;中位年龄65岁(IQR 57-70),58%男性,66%白人,约三分之一有≥3种合并症;57%实体瘤,42%血液肿瘤;69%近90天接受抗肿瘤治疗。
- 干预与对照:无干预。
- 主要终点结果:医院死亡率45%(40/89);机械通气者死亡率53%(32/60)。
- 关键次要终点:67%需机械通气,56%需俯卧位,28%行气管切开,71%需血管活性药;ICU和医院住院时间分别为10天和26天;9个月随访死亡率54%(48/89)。
- 与更高医院死亡率显著相关的因素:血液肿瘤、更高疾病严重度与器官衰竭评分、需要有创机械通气及血管活性药、入ICU时较低血红蛋白和血小板计数、较高D-二聚体。
证据类型、等级与局限
- 证据类型:单中心回顾性队列研究。
- 证据等级或推荐强度:原文未提及。
- 局限:单中心、回顾性、样本量小(89例)、无对照组、无干预;原文未提及其他局限。
对床旁实践的改变
- 原文未提及
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: Adult patients with cancer have a greater likelihood of developing severe illness and death from coronavirus disease 2019 compared with patients without cancer. We sought to characterize the clinical characteristics and outcomes of cancer patients who tested positive for severe acute respiratory syndrome coronavirus 2 and were admitted to the ICU at the peak of the first wave of the pandemic in the United States.
DESIGN: A single-center retrospective cohort study.
SETTING: Two medical-surgical ICUs of a tertiary-care cancer center.
PATIENTS/SUBJECTS: All consecutive adult patients (≥ 18 yr) with current or past (< 2 yr) diagnosis of cancer who were admitted to the ICU with coronavirus disease 2019 between March 1, and June 30, 2020.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Demographic, clinical, and laboratory data of 89 critically ill cancer patients were extracted from electronic medical records. Median age was 65 years (interquartile range, 57-70 yr), 66% were White, and 58% male. Approximately a third of patients had three or more comorbidities. Fifty-one patients (57%) had solid tumors, and 38 (42%) had hematologic malignancies. Sixty-one patients (69%) received cancer-directed therapy within the previous 90 days. Sixty patients (67%) required mechanical ventilation, 56% required prone positioning, 28% underwent tracheostomy, and 71% required vasopressors. Hospital mortality was 45% (40/89). Among those who required mechanical ventilation, mortality was 53% (32/60). Hospital mortality was significantly higher among patients with hematologic malignancies, higher severity of illness and organ failure scores, need for invasive mechanical ventilation and vasopressor therapy, lower hemoglobin and platelet count, and higher d-dimer levels at ICU admission. ICU and hospital length of stay were 10 and 26 days, respectively. At 9-month follow-up, the mortality rate was 54% (48/89).
CONCLUSIONS: We report the largest case series and intermediate-term follow-up of cancer patients with coronavirus disease 2019 who were admitted to the ICU. Hospital mortality was 45%. Intermediate-term outcome after hospital discharge was favorable.
参考来源
- Dang MKM, Bhatt I, Dulu AO, et al. Clinical Characteristics, Management, and Outcomes of Cancer Patients With Coronavirus Disease 2019 Admitted to the ICU. Crit Care Explor. 2021. PMID: 34514429. doi:10.1097/CCE.0000000000000535
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。